CAR-T – Talk Bio

Descartes-08: Sustained Efficacy in Myasthenia Gravis as Cartesian Prepares for Phase III Trial

2 weeks ago talkbio0Tagged Autoimmune Diseases, Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes, CAR-T, Cartesian, Clinical Trials, gMG, mRNA-based, Myasthenia Gravis, Phase III AURORA trial

Descartes-08 , Myasthenia Gravis (gMG) , CAR-T therapy , Cartesian Therapeutics , mRNA-based treatment , Phase III AURORA trial , Autoimmune diseases , Clinical trial results

Cabaletta’s CABA-201 CAR-T Therapy Shows Promising Results in Lupus and Other Autoimmune Diseases

2 months ago talkbio0Tagged Autoimmune Diseases, B-Lymphocytes, CABA-201, CAR-T, Clinical Trials, Lupus Vulgaris

CABA-201, CAR-T therapy, lupus, autoimmune diseases, clinical trials, remission, B cell depletion

Catalent and Galapagos Collaborate on Decentralized CAR-T Manufacturing; Kindeva Secures $129M Contract for Nerve Agent Antidote

3 months ago talkbio0Tagged Antidote, CAR-T, Catalent, decentralized, Duodote, Galapagos, Kindeva, Lymphoma, Non-Hodgkin, Manufacturing, Nerve Agents, NHL, Strategic National Stockpile

Catalent, Galapagos, CAR-T therapy, Decentralized manufacturing, Non-Hodgkin lymphoma (NHL), Kindeva Drug Delivery, DuoDote, Nerve agent antidote, Strategic National Stockpile

Umoja Biopharma Advances In Situ CAR-T Therapy with FDA Clearance and $100M Series C Funding

3 months ago talkbio0Tagged CAR-T, Clearance, Hematologic Neoplasms, in situ, Series, UB-VV111, Umoja Biopharma, United States Food and Drug Administration

Umoja Biopharma, CAR-T therapy, in situ, UB-VV111, FDA clearance, hematologic malignancies, Series C funding

Astellas Terminates Development of Autologous Cell Therapy for Lymphoma Following Pipeline Review

3 months ago talkbio0Tagged Astellas, Autologous (qualifier value), Biotechnology, Cancer Therapeutic Procedure, CAR-T, Cell Therapy, Lymphoma, Pipeline Review

Astellas, lymphoma, CAR-T cell therapy, autologous cell therapy, pipeline review, cancer treatment, biotechnology

From Partnership to Acquisition: The $1.5 Billion Journey of Roche and Poseida Therapeutics

4 months ago talkbio0Tagged Acquisition, allogeneic cell therapy, biotech, CAR-T, Drug Industry, Genetic, genetic medicines, Poseida Therapeutics/ Inc., Roche (company)

Roche Holdings/ Inc., Poseida Therapeutics/ Inc., Allogeneic cell therapy, CAR-T programs, Genetic medicines, Biotech acquisition, Pharmaceutical industry